La vendita allo scoperto per Kiora Pharmaceuticals dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Kiora Pharmaceuticals. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Kiora Pharmaceuticals (NASDAQ:KPRX) Azioni, Report sulle vendite allo scoperto

Kiora Pharmaceuticals

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals Inc

Rand Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAND#NASDAQ">RAND</a>) reported quarterly earnings of $0.46 per share. This is a 58.62 percent increase over earnings of $0.29 per share from the same period last year. The company reported $2.22 million in sales this quarter. This is a 27.40 percent increase over sales of $1.74 million the same period last year.

Earnings

News

RAND

Rand Capital Q3 Adj $0.46 Up From $0.29 YoY, Sales $2.22M Up From $1.74M YoY

WIIM

WTRG

Essential Utilities shares are trading higher after Baird maintained an Outperform rating on the stock and raised its price target from $45 to $46.

Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) has cautioned investors about the uncertain profitability of future products as the tech giant pivots towards emerging markets, including artificial intelligence and virtual reality.
With a new addition to its annual report&#8217;s &#8220;risk factors,&#8221; Apple warned that some upcoming offerings might not match the revenue and profit margins of the flagship iPhone line, the Financial Times <a target="_blank" href="https://www.ft.com/content/e30eb646-a7ad-496e-8fa4-ff1b4445e853" rel="noreferrer noopener">reports</a>.
Apple also flagged potential challenges from &#8220;geopolitical tensions&#8221; in its latest filing, alongside safety risks tied to AI integrations.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/11/41757088/fox-corps-political-ad-revenue-surges-tubi-growth-sparks-analyst-optimism" rel="noreferrer noopener">Fox Corp&#8217;s Political Ad Revenue Surges, Tubi Growth Sparks Analyst Optimism</a>
These concerns coincide with Apple&#8217;s push to keep pace with competitors like Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google and Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) in the AI sector, where it has recently launched new &#8220;Apple Intelligence&#8221; features and expects to integrate ChatGPT into Siri.
Amid regulatory scrutiny, Apple faces pressure over its high-margin services, including the App Store, as recent U.S. antitrust actions threaten licensing revenue from deals with Google.
This shift in focus comes as Apple broadens its product lineup to sustain revenue. Its Vision Pro headset, a &#8220;spatial computing&#8221; device priced at $3,499, marks the company&#8217;s latest attempt at diversifying its hardware portfolio, though sales remain modest.
Meanwhile, the company&#8217;s services business, contributing a gross margin of over 70%, has helped bolster profitability and offset slowing iPhone growth.
Apple&#8217;s gross margin, which hovered around 33% when the iPhone launched in 2007, has risen to over 40% as demand for high-end models increases.
BofA Securities analyst Wamsi Mohan projected a <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41722824/apples-services-and-silicon-strategy-to-fuel-margins-justify-high-valuation-analyst" rel="noreferrer noopener">robust iPhone upgrade</a> cycle in 2025 and 2026, fueled by demand for Gen AI capabilities, increasing Services revenue, higher margins from Apple&#8217;s in-house silicon, continued capital returns, and expanded AI-driven institutional interest.
Mohan expects minimal impact from the EU Digital Markets Act on Apple&#8217;s App Store performance.
Needham&#8217;s Laura Martin&nbsp;estimates <a target="_blank" href="https://www.benzinga.com/news/24/09/41005053/apple-iphone-to-fuel-96-of-2025-revenue-analyst-says-a-safer-bet-than-ai-heavy-amazon-alphabet-micro" rel="noreferrer noopener">iPhone sales to</a> account for 89%-96% of Apple&#8217;s 2025 revenue.
Apple stock has gained over 20% year-to-date. Investors can gain exposure to the stock through the iShares Core S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVV#NYSE">IVV</a>) and the Vanguard Total Stock Market ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTI#NYSE">VTI</a>).
Price Action: At the last check on Wednesday, AAPL stock traded higher by 0.48% to $224.53 premarket.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41756372/robinhoods-election-contracts-hit-200-million-trades-on-election-day" target="_blank" rel="noreferrer noopener">Robinhood&#8217;s Election Contracts Hit 200 Million Trades On Election Day</a></li>
</ul>
Image via Shutterstock

Tech

Media

AAPL

GOOG

GOOGL

Apple Signals Profit Risks in AI and VR Shift: What It Means for Investors?

Elon Musk is a household name now, but his mom, <a href="https://www.benzinga.com/startups/24/08/40291162/elon-musks-76-year-old-mom-sleeps-in-garage-or-on-the-floor-when-she-visits-billionaire-son-its-bett">Maye Musk</a>, saw the spark in him long before the rest of the world.&nbsp;
Maye reminisced about Elon&#8217;s early years in a 2021 interview on CBS This Morning to promote her memoir A Woman Makes a Plan. The Tesla and SpaceX founder was constantly in the headlines for his success, but Maye wasn't surprised. According to her, she had known since he was a toddler that Elon had a rare kind of mind.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li><a href="https://www.benzinga.com/money/100k-cd">$100K Sitting In A CD Account, Should I Move Money Into The Stock Market?</a></li>
</ul>
"At 3, I knew he was a genius," she said, quickly adding that it didn't automatically mean he'd succeed. "You still don't know if he's going to do great things because many geniuses end up in a basement being a genius but not applying it."
Picture it: a young Elon, just a few years old, with a mind that was already racing. But Maye, like any mother, had a practical side. Sure, she knew her son was special, but the thought crossed her mind – what if he ended up as a recluse, tinkering away in some basement? It's a funny image now, considering that potential "basement genius" has <a href="https://www.benzinga.com/personal-finance/24/09/40799246/elon-musks-ex-wife-and-mom-of-5-says-he-was-willing-to-give-up-his-fortune-for-space-goals-even-">morphed into a multibillionaire</a> who, quite literally, aims for the stars.
Trending: Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.
Maye watched Elon's mind start taking on big problems at an early age. "I was so excited when he started Zip2 because it just made life easier with door-to-door directions and then newspapers could have a link that took you to a restaurant," she explained. That sounds routine now, but back then, Maye noted, "People didn't believe that that's possible and so that's why I invested in that at the very beginning." She saw what others couldn't yet see – a digital world that Elon would help shape.
But Elon wasn't the type to stop at one venture. According to Maye, it was almost like he couldn't help himself. "And then, of course, he thought the banking system needed some help, so then he did PayPal," she said.&nbsp;
Trending: This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.
It's classic Elon – spotting inefficiencies and jumping in to solve them. She even tried to rein him in a little when he started eyeing even bigger ambitions: "I said just choose one and of course, he didn't listen to me." And thank goodness he didn't. Where would we be if Elon Musk had picked just one? No electric cars, no private rockets, no flamethrowers, for that matter.
Fast-forward to now and Elon's relentless ambition hasn't just made him successful; it's made him the richest person on the planet. With a net worth of $263 billion, he's <a href="https://www.benzinga.com/personal-finance/24/09/41004802/elon-musks-little-sister-says-prices-skyrocket-when-people-find-out-shes-related-to-the-richest-">crossed financial milestones</a> in almost incomprehensible ways. In October alone, his wealth reportedly surged by $34 billion in a single day due to a <a href="https://www.benzinga.com/startups/24/10/41642511/frustrated-by-teslas-inability-to-repair-his-cybertruck-man-used-a-12-part-heres-how-he-solved-the-i">spike in Tesla's stock – </a>a figure most people can't imagine.
See Also: According to Vanguard&#8217;s Advisor&#8217;s Alpha Study, working with a financial advisor can result in approximately 3% higher net returns annually,<a href="https://www.benzinga.com/money/3-percent-advantage-financial-advisor"> here are the benefits of partnering with a financial advisor and how to find the right one near you in minutes.</a>
Maye's early fears of a basement-bound genius were more than unfounded; they now feel almost comical. Instead of hiding away, Elon Musk transformed his genius into groundbreaking companies that have changed entire industries.&nbsp;
Her pride is clear and her reflections capture a sense of wonder and humor that only a mother can have. She knew Elon was different from Day One – but even she couldn't have predicted just how far he'd go by simply refusing to "pick just one."
Read Next:
<ul>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on how on what&#8217;s behind this formula.</a></li>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
</ul>

Personal Finance

Elon Musk's Mom Knew He Was A 'Genius' By 3 Years Old But Worried He'd 'End Up In A Basement' – Now He's The Richest Man In The World

Contracts

KOPN

Kopin Announces That Startup Get Your Way Selected Co.'s Golden Pearl Optical Module For Its aRdent 2 Assisted Reality Solution

Says Medical Insurance Probe Is "Historic", In Past, Not Involving Any Current Executives; Medical Insurance Probe Began Three Years Ago, Initially Involved Small Number Of Employees; Now 100 Former Employees Have Been Sentenced To Jail Time
-Investor Call

AstraZeneca Says Arrests Of Current And Former Staff Mentioned By CEO In September To Bloomberg Are A Third Issue, Unrelated To Medical Insurance And Wang Investigations; Sought To Quell Concerns About China Business After Report Of Broader Probe Into Potential Insurance Fraud; China Exec. Leon Wang Is Detained By Chinese Authorities As Part Of The Investigation; To The Company's Knowledge; Medical Insurance Probe Reported By Yicai Is Separate From The Leon Wang Investigation

Guidance

Pinnacle West Capital  Estimates 2025 EPS Of $4.40 - $4.60 On Weather-normalized Basis, Est $4.78

IGC Pharma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) ("IGC Pharma" or the "Company") is pleased to announce the publication of a new interview with CEO Ram Mukunda, now available as part of the IMS Spotlight Series.
In the interview, Ram Mukunda discusses IGC's strategic expansion into metabolic and neurological markets, specifically addressing the potential of GLP-1 agonists in both Alzheimer's and weight loss therapies. Mukunda also provides updates on IGC Pharma's lead candidate, IGC-AD1, which is currently in Phase 2 trials for treating agitation in Alzheimer's dementia and is progressing toward additional trials to explore its potential as a disease-modifying treatment.
The interview underscores IGC's approach to leveraging artificial intelligence to diversify its pipeline, targeting both neurodegenerative and metabolic disorders to maximize patient impact.
To read the full interview, please visit: <a href="https://pr.report/41tx">Expanding Our Portfolio: IGC Pharma's Strategic Growth in Alzheimer's and Weight Loss Therapies</a>

Biotech

General

IGC Pharma Announces Publication Of IMS Spotlight Interview With CEO Ram Mukunda Highlighting Strategic Expansion In Alzheimer's And Weight Loss Therapies

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>)</h3>
<ul>
<li>Dividend Yield: 3.05%</li>
<li>Citigroup analyst Andrew Baum maintained a Buy rating and cut the price target from $60 to $40 on Oct. 25. This analyst has an accuracy rate of 72%.</li>
<li>Morgan Stanley analyst Terence Flynn maintained an Overweight rating and raised the price target from $48 to $51 on July 11. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On Nov. 4, Royalty Pharma and Syndax Pharmaceuticals entered into $350 million royalty funding agreement for Niktimvo.</li>
<li>Benzinga Pro's real-time newsfeed alerted to l<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">atest RPRX news. </a></li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/21cac52e-a5a5-4623-954e-111f57f53a6d" alt="" style="width:638px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</h3>
<ul>
<li>Dividend Yield: 3.13%</li>
<li>Citigroup analyst Joanne Wuensch maintained a Buy rating and raised the price target from $180 to $185 on Oct. 16. This analyst has an accuracy rate of 77%.</li>
<li>Wells Fargo analyst Larry Biegelsen maintained an Equal-Weight rating and increased the price target from $163 to $166 on Oct. 16. This analyst has an accuracy rate of 72%.</li>
<li>Recent News: On Oct. 28, Johnson &amp; Johnson announced results from the Phase 3 GRAVITI study of Tremfya (guselkumab) for Crohn's disease.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"> latest JNJ news.</a> </li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/572ca32b-5a3e-4fc3-b873-df0527702e1f" alt="" style="width:659px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>)</h3>
<ul>
<li>Dividend Yield: 3.12%</li>
<li>Truist Securities analyst Richard Newitter maintained a Hold rating and raised the price target from $90 to $93 on Oct. 14. This analyst has an accuracy rate of 74%.</li>
<li>Citigroup analyst Joanne Wuensch maintained a Neutral rating and increased the price target from $85 to $92 on Oct. 1. This analyst has an accuracy rate of 77%.</li>
<li>Recent News: Medtronic will report financial results for its second quarter of fiscal year 2025 on Tuesday, Nov. 19.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">trend in MDT stoc</a>k. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="906" height="841" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48.png" alt="" class="wp-image-632327" style="width:589px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48-768x713.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a>

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

RPRX

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields

Broadridge Financial Solutions shares are trading higher after Morgan Stanley raised its price target on the stock from $200 to $207.

Keybanc analyst Eric Gonzalez maintains Restaurant Brands Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSR#NYSE">QSR</a>) with a Overweight and lowers the price target from $80 to $78.

Keybanc Maintains Overweight on Restaurant Brands Intl, Lowers Price Target to $78

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58d94a96b85e930001fd9dd4/kevin-dede">HC Wainwright &amp; Co. analyst Kevin Dede</a> initiated coverage on BitFuFu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUFU#NASDAQ">FUFU</a>) with a Buy rating and announced a price target of $7. BitFuFu shares closed at $4.57 on Tuesday. <a href="https://www.benzinga.com/quote/FUFU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst David Katz initiated coverage on Ryman Hospitality Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHP#NYSE">RHP</a>) with a Buy rating and announced a price target of $130. Ryman Hospitality shares closed at $108.30 on Tuesday. <a href="https://www.benzinga.com/quote/RHP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/61826cd080db050001bbb18a/jiong-shao">Barclays analyst Jiong Shao</a> initiated coverage on Vipshop Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIPS#NYSE">VIPS</a>) with an Overweight rating and announced a price target of $19. Vipshop shares closed at $14.58 on Tuesday. <a href="https://www.benzinga.com/quote/VIPS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Gary Mobley initiated coverage on Rambus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) with an Overweight rating and announced a price target of $62. Rambus shares closed at $50.26 on Tuesday. <a href="https://www.benzinga.com/quote/RMBS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein analyst Lee Hambright initiated coverage on Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with an Outperform rating and announced a price target of $300. Insulet shares closed at $241.32 on Tuesday. <a href="https://www.benzinga.com/quote/PODD/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PODD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="582" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083542/image-51-1024x582.png" alt="" class="wp-image-632774" style="width:633px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083542/image-51-1024x582.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083542/image-51-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083542/image-51-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083542/image-51.png 1178w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a></li>
</ul>

Initiation

FUFU

PODD

RMBS

VIPS

This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

LQR House Inc. (the "Company" or "LQR House") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQR#NASDAQ">LQR</a>), a niche e-commerce platform specializing in the spirits and beverage industry,is thrilled to announce a new marketing collaboration with The New York Cocktail Co., including a launch of a custom campaign highlighting their award-winning ready-to-drink cocktail Negroni, crafted by their team of New York's bartenders. This campaign will focus on driving traffic and sales for their bottled Negroni cocktail on <a href="https://pr.report/41m0">CWSpirits.com</a>.
According to The New York Cocktail Co., their Negroni is more than just a cocktail; it offers convenience without compromising quality, capturing the essence of the bartender-guest connection in every pour. It stands as a tribute to Dante NYC-an iconic Greenwich Village café and a landmark in New York's cocktail scene since 1915. Renato Tonelli, an Italian-American Beverage Director at Dante and the 2023 U.S. Bartender of the Year, has brought his expertise to create this spirited, herbaceous, and impeccably balanced Negroni, now bottled for The New York Cocktail Co.

LQR House Announces Marketing Partnership With The New York Cocktail Co. To Drive Awareness And Sales Of Their Negroni Cocktail On CWSpirits.com

Pinnacle West Capital Adjusts 2024 EPS Guidance Upward From $4.60 - $4.80 To  $5.00 - $5.20, Est $4.85

Tencent Music shares are trading lower. Barclays initiated coverage on the stock and announced a price target of $16.

Nvni Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) ("Nuvini"), a leading B2B SaaS acquirer in Latin America, is pleased to announce the successful close of its latest financing round, consisting of a combination of equity and convertible notes. The financing, led by Nuvini's Founder and CEO, Pierre Schurmann, and existing investors, underscores the company's strategic growth vision.
The convertible notes were secured at a conversion price of $1.10 per share. The premium pricing signals not only the company's founder and investors' belief in the company's resilience and growth potential but also a shared commitment to building a robust foundation for sustainable, long-term expansion.
In addition to this strategic financing milestone, Nuvini is pleased to announce the promotion of Mr José Mario Ribeiro to the role of Chief Operating Officer. Since the announcement of Jose Mario as Board Advisor in August, he has made significant contributions to the company, and his transition to this expanded role will enable Nuvini to accelerate its focus on embedding finance within its portfolio companies, further amplifying operational efficiencies and growth opportunities.

Management

NVNI

Nuvini Appoints José Mario Ribeiro As New Chief Operating Officer

REBN

Reborn Coffee Announced It Has Closed Its Acquisition Of A 58% Stake In South Korean Bbang Ssaem Bakery; Terms Not Disclosed

Jones Lang LaSalle shares are trading higher after the company reported better-than-expected Q3 financial results.

The Company's innovative alcohol-reducing beverage, Sure Shot, will be available in 450+ stores across the Chicago area.
JUPITER, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOT#NASDAQ">SHOT</a>) ("Safety Shot" or "the Company") today announced a new distribution agreement with Huckster, Inc., a leading Direct-to-Store (DSD) distributor in Illinois, to expand the availability of its innovative alcohol-reducing beverage, Sure Shot, in the metro Chicago market.
Sure Shot, the first beverage of its kind, is specifically formulated to reduce blood alcohol content while enhancing mental clarity. Its unique blend of essential B vitamins, antioxidants, electrolytes, and nootropics supports the body's natural metabolic processes to efficiently process alcohol, reducing blood alcohol content (BAC) in as little as 30 minutes. This innovative approach, backed by a recently awarded patent and positive clinical study results, positions Sure Shot as the ideal choice for health-conscious individuals who enjoy an active social life.

SHOT

Safety Shot Expands Reach In Metro Chicago With New Distribution Agreement With Huckster, Inc.

Keybanc analyst Steve Barger downgrades Myers Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYE#NYSE">MYE</a>) from Overweight to Sector Weight.

Downgrades

Keybanc Downgrades Myers Indus to Sector Weight

Maxim Group analyst Michael Okunewitch maintained a Buy rating on Kiora Pharmaceuticals (KPRX – Research Report) yesterday and set a price target o...

Buy Rating on Kiora Pharmaceuticals Amid Strong Financials and Promising Clinical Trials

Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Kiora Pharmaceuticals (KPRX – Research Report), retaining the price target of $2.00. ...

Buy Rating for Kiora Pharmaceuticals Bolstered by Strong Financials and Promising Clinical Trial Data

The latest announcement is out from Kiora Pharmaceuticals (KPRX). The Company has made headlines by announcing Ms. Walters-Hoffert's appointment to...

Kiora Pharmaceuticals Announces Board Appointment, Regains Nasdaq Compliance

Kiora Pharmaceuticals GAAP EPS of -$0.53 beats by $0.33

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Kiora Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/kprx-stock-quote/">KPRX</a>) just reported results for the second quarter of 2024.<ul><li>Kiora Pharmaceuticals reported earnings per share of -53 cents. This was above the analyst estimate for EPS of -81 cents.</li><li>The company reported revenue of $20,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/kprx-stock-earnings-kiora-pharmaceuticals-for-q2-of-2024/">KPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

KPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q2 2024

Analyst Michael Okunewitch of Maxim Group maintained a Buy rating on Kiora Pharmaceuticals (KPRX – Research Report), with a price target of $27.00....

Buy Rating on Kiora Pharmaceuticals: Strong Financials and Promising KIO-301 Progress

Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Kiora Pharmaceuticals (KPRX – Research Report), retaining the price target of $10.00....

Buy Rating on Kiora Pharmaceuticals Amid Promising Clinical Trials and Strong Financials

Kiora Pharmaceuticals ( ($KPRX) ) has issued an update. Kiora Pharmaceuticals has received regulatory approval to begin a Phase 2 clinical trial of...

Comments

Kiora Pharmaceuticals

Vendite allo scoperto

Kiora Pharmaceuticals (NASDAQ:KPRX) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO